Drug Trial Radar · NCT06872489
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Second Life TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 12, 2025
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 2 years
Summary
As written by the sponsor on the registry.
This is an Expanded Access Program (EAP) that will give the participants access to the drug SL-28 before it is approved by the FDA. Participants in this study will have Advanced Solid Tumors who failed to respond to standard therapy (chemotherapy, immunotherapy) or developed progressive disease at any phase of standard therapy. Researchers think the SL-28 will be effective because SL-28 has a direct activity against different types of tumors. SL-28 is a cell-based therapy, based on leukocytes isolated from healthy donors and are activated through the proprietary process. After quality assessment (sterility, viable cell count, purity, and absence of infectious diseases), they are stored at -80°C until use. Upon need, the SL-28 is thawed, followed by checking their viability, count, and sterility. Adult and older adult patients aged 18 to 65+ who meet the eligibility criteria will be included in the study. Patients receive SL-28 IV once daily on days 1-5 and 8-12. Based on the patient's response, the need for additional injections will be evaluated. If improvements in the patient's condition are confirmed by MRI, further injections can continue on a rate 5 days a week.
Conditions
- Neuroblastoma in Children
- Neuroblastoma, Recurrent, Refractory
- Advanced Cancer
- Advanced Malignant Neoplasm
- Prostate Cancer Patients With Bone Metastasis
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Lung Cancer - Non Small Cell
- Gastrointestinal Cancers
- Head and Neck Cancer
- Pancreatic Cancer
Interventions
SL-28.Biological
Allogeneic, non-HLA matched, Leucocyte-Tells-based therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.